🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the pathogen, according to researchers.

An International Challenge

Cases of gonorrhoea are escalating worldwide, with figures suggesting more than 82 million new cases per year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the highly restricted treatment choices currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists hope that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This approval signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Outcomes and Global Access

As per findings published in a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The study involved over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Doctors treating patients have shared positive views. Having a one-pill regimen like this is described as a "critical tool" for public health efforts. This is considered vital to lessen the impact of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.